News for hackers. Stuff that matters.
Re:Doctors have reversed an inherited disorder in utero usin... by rayiner on Thursday April 26, 2018 @07:46AM (#16930989)
It's interesting that lead billing goes to the doctors who injected the drug into a pregnant woman rather than the pharmaceutical company that developed it. "Doctors" cure patients of disease; "drug companies" rip off consumers.
Re:Doctors have reversed an inherited disorder in utero usin... by victor106 on Thursday April 26, 2018 @08:46AM (#16931336)
“Drug companies rip off consumers”

That is an extremely glib view. There are “some” drug companies that rip off people. The problem with pricing in the Rx world is the high cost and unpredictable nature of discovering new drugs.

Profit margin of tech companies is twice that of Rx companies. Would you say that tech companies are ripping people off?

http://www.businessinsider.com/sector-profit-margins-sp-500-...

Re:Doctors have reversed an inherited disorder in utero usin... by bkmartin on Thursday April 26, 2018 @09:25AM (#16931609)
The chart you reference shows that they are virtually the same...

All of Health vs All of Tech - yes, you are right. Tech is about double.

But Pharma, Biotech, Life Sciences show better returns over Tech as a whole and virtually equivalent Software & Services return.

I would argue that there are definitely players in the Tech space that are raking some very hefty profits, but are in highly competitive markets that could see that erode into losses very quickly... I do not think we are quite in the realm of price gouging and the lower barriers to entry in most of tech keeps things from swinging too far off the charts.

Re:Doctors have reversed an inherited disorder in utero usin... by vibrio on Thursday April 26, 2018 @09:40AM (#16931725)
One should consider any survivorship bias in thinking about that. Also consider that a series A in biopharma is commonly well above above $30MM, and that doesn't generally even come close to funding proof-of-concpet clinical studies. That combined with any survivorship bias complicates the economic interpretations of cross industry profit margins.
Re:Doctors have reversed an inherited disorder in utero usin... by bkmartin on Friday April 27, 2018 @11:04AM (#16941267)
That doesn't really apply here does it? My comment is only in reference to S&P500 companies, that the OP to my comment referenced.
Re:Doctors have reversed an inherited disorder in utero usin... by posterboy on Thursday April 26, 2018 @11:15AM (#16932617)
Strawman fallacy!

Please stay on-topic! Well, Facebook is collecting data and selling it to pharma companies for probably more than advertising, I suppose. Yes, they are part of the problem. I'm not generalizing who's at fault, but there is a problem.

Re:Doctors have reversed an inherited disorder in utero usin... by mikeash on Thursday April 26, 2018 @09:42AM (#16931738)
How much credit should an inventor get if their invention doesn’t work, they can’t make it work, they go out of business and stop working on it, then someone else comes along and figures out how to use it for something useful? I’m not sure what the right answer is exactly, but it seems right to give the second person a substantial part of the credit at least.
Re:Doctors have reversed an inherited disorder in utero usin... by maxerickson on Thursday April 26, 2018 @09:48AM (#16931785)
The mother/parents was/were the one that decided it was a good idea. The doctor and university were willing to do the paperwork or whatever.

It's not really even an invention, it's a human protein that was probably identified in academic research a long time before the company decided to produce it and see if it could be used as a treatment.

Re:Doctors have reversed an inherited disorder in utero usin... by _Microft on Thursday April 26, 2018 @08:00AM (#16931063)
The drug did work in animal tests on pregnant animals but failed to work on born children. It was the couple who approached the doctor asking to try it during pregnancy already. The doctor and his university agreed to administer the drug under a “compassionate use” exemption.

The pharmaceutical company was not directly involved in this.